Add BrightSurf on Google Email

Proof that PUMA stalks cancer cells solves long-standing mystery of the anti-cancer role of p53

Researchers at St. Jude Children's Research Hospital have discovered that PUMA is the primary mediator of cell death in response to p53 signals, leading to apoptosis in cancer cells. The study provides critical insights into how cancer disrupts a failsafe mechanism that kills abnormal cells, and offers potential new therapy targets.

How AIDS destroys immunity

Researchers found that the HIV vpr gene exploits the normal repair process of cells to stop vital white blood cells from replicating, thus disabling the immune system. The study suggests a possible treatment for AIDS-related immune-system damage using medicines that prevent the human ATR gene from being activated by HIV's vpr gene.

SourceUniversity of Utah Health·JournalJournal of Biological Chemistry·DateAug 20, 2003

Cancer could be caught before it develops

Researchers Jules Berman and Donald Henson developed a classification system for cancer precursors, identifying 568 distinct concepts with over 4700 terms. This database is designed to be fully searchable and linked to other databases, providing a potential breakthrough in early detection and treatment.

SourceBMC (BioMed Central)·JournalBMC Medical Informatics and Decision Making·DateJun 20, 2003

UT Southwestern researchers find immune system stages for eliminating viral infections, cancer cells

Researchers at UT Southwestern Medical Center have partially uncovered the stages in the elimination of viral infections and cancer cells by the human immune system. The study found that natural killer cells and cytotoxic T cells use different mechanisms to kill target cells, with significant differences in their roles and receptor usage.

SourceUT Southwestern Medical Center·JournalProceedings of the National Academy of Sciences·DateJun 9, 2003

Equine cloning may shed light on human cancer causes

Researchers have discovered that equine cloning can provide insights into human cancer causes, particularly in relation to calcium levels within cells. The study found that horses have lower intracellular calcium and slower cell activity rates compared to humans, which may contribute to their lower mortality rate from metastatic cancer.

SourceUniversity of Idaho·JournalScience·DateMay 29, 2003

Microgel polymer beads may provide general vehicle for vaccines, gene therapy

Researchers have developed microgel polymer beads that can be engineered to break apart in acidic conditions, releasing vaccine antigens on the surface of immune cells. This technique avoids destroying protein antigens with stomach acids, making it a promising approach for future vaccines and gene therapy.

SourceUniversity of California - Berkeley·JournalProceedings of the National Academy of Sciences·DateApr 25, 2003

Researchers create DNA 'nanocircles' to probe the mystery of aging in human cells

Scientists at Stanford University have created synthetic DNA nanocircles that can lengthen telomeres in test tube cells, a key factor in determining cell lifespan. This breakthrough could lead to the development of new methods for studying aging and cancer, as well as alternative approaches to transplantation medicine.

SourceStanford University·JournalProceedings of the National Academy of Sciences·DateNov 19, 2002

Chemists show proteins behave differently inside cells than they do in water solutions

Researchers at UNC Chapel Hill used nuclear magnetic resonance spectroscopy to study the effects of crowded environments on protein shape. They found that intrinsically unstructured proteins exhibit a definite folded-up shape when inside cells, unlike their apparent lack of structure in water solutions.

SourceUniversity of North Carolina at Chapel Hill·JournalProceedings of the National Academy of Sciences·DateSep 13, 2002

Newer lung cancer treatments extend survival longer than traditional regimens

This study found that paclitaxel- and carboplatin-based regimens can prolong survival of patients with advanced non-small cell lung cancer, with two-year survival rates similar to those achieved at one year with best supportive care. However, three-drug regimens were slightly more toxic and did not provide additional benefits.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateJun 27, 2002